Investors sold shares of Amgen Inc. (NASDAQ:AMGN) on strength during trading hours on Wednesday. $63.25 million flowed into the stock on the tick-up and $100.60 million flowed out of the stock on the tick-down, for a money net flow of $37.35 million out of the stock. Of all equities tracked, Amgen had the 0th highest net out-flow for the day. Amgen traded up $0.76 for the day and closed at $163.25

Several brokerages have issued reports on AMGN. Zacks Investment Research raised shares of Amgen from a “hold” rating to a “buy” rating and set a $166.00 target price for the company in a report on Wednesday, June 29th. Vetr raised shares of Amgen from a “hold” rating to a “buy” rating and set a $159.50 target price for the company in a report on Monday, June 13th. Morgan Stanley reaffirmed a “buy” rating and issued a $195.00 target price on shares of Amgen in a report on Friday, April 29th. Leerink Swann reaffirmed a “hold” rating on shares of Amgen in a report on Sunday, June 26th. Finally, Jefferies Group reaffirmed a “buy” rating and issued a $187.00 target price on shares of Amgen in a report on Wednesday, July 13th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $181.19.

The firm has a 50-day moving average price of $155.69 and a 200 day moving average price of $152.84. The company has a market capitalization of $122.64 billion and a PE ratio of 17.28.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Thursday, April 28th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.60 by $0.30. The business had revenue of $5.53 billion for the quarter, compared to analysts’ expectations of $5.32 billion. The business’s quarterly revenue was up 9.8% compared to the same quarter last year. During the same period in the prior year, the business posted $2.48 earnings per share. Equities research analysts expect that Amgen Inc. will post $11.17 EPS for the current year.

In other news, EVP Madhavan Balachandran sold 30,000 shares of Amgen stock in a transaction that occurred on Wednesday, May 4th. The shares were sold at an average price of $154.12, for a total transaction of $4,623,600.00. Following the completion of the transaction, the executive vice president now directly owns 23,097 shares of the company’s stock, valued at approximately $3,559,709.64. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Sean E. Harper sold 21,875 shares of Amgen stock in a transaction that occurred on Friday, April 29th. The shares were sold at an average price of $157.99, for a total transaction of $3,456,031.25. Following the transaction, the executive vice president now directly owns 42,248 shares of the company’s stock, valued at $6,674,761.52. The disclosure for this sale can be found here.

Other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its position in Amgen by 2.2% in the fourth quarter. Vanguard Group Inc. now owns 44,916,785 shares of the medical research company’s stock valued at $7,291,342,000 after buying an additional 953,984 shares during the period. Marshall Wace LLP raised its position in Amgen by 9,486.1% in the fourth quarter. Marshall Wace LLP now owns 412,300 shares of the medical research company’s stock valued at $66,929,000 after buying an additional 407,999 shares during the period. Morgan Stanley raised its position in Amgen by 5.4% in the fourth quarter. Morgan Stanley now owns 7,317,025 shares of the medical research company’s stock valued at $1,187,772,000 after buying an additional 373,979 shares during the period. Bank of Montreal Can raised its position in Amgen by 14.3% in the fourth quarter. Bank of Montreal Can now owns 2,648,382 shares of the medical research company’s stock valued at $429,912,000 after buying an additional 332,329 shares during the period. Finally, Montag & Caldwell LLC raised its position in Amgen by 24.6% in the fourth quarter. Montag & Caldwell LLC now owns 1,028,442 shares of the medical research company’s stock valued at $166,947,000 after buying an additional 203,350 shares during the period.

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.